Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

CureVac AG. (1/8/19). "Press Release: CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants against RSV". Tübingen & Boston, MA.

Region Region United States (USA)
Organisations Organisation CureVac AG
  Today CureVac SE
  Group CureVac (Group)
  Organisation 2 US Patent and Trademark Office (USPTO)
  Group United States (govt)
Products Product vaccine, RSV
  Product 2 mRNA-based vaccine
Persons Person Gordon, Jenn (Global Health PR 201901)
  Person 2 Beck, Matthew L. S. (Matt) (Hookipa 202210 Investor Relations before CureVac + Solebury Trout)

Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that the U.S. Patent and Trademark Office (USPTO) has granted a fundamental patent for the use of mRNA encoding the Respiratory Syncytial Virus (RSV) F-protein for vaccination of infants up to two years of age (US Patent No. 10,172,935). The F-protein is the major antigen of RSV and forms the basis of potential future RSV vaccines. The USPTO already granted a similar patent in 2017 that relates to vaccination of infants for the prophylaxis of influenza. Moreover, similar patents have already been granted to CureVac in Europe and Japan. Together, these broad technology patents strengthen CureVac’s industry-leading position in the mRNA space as the Company develops preventative vaccine candidates for severe infectious diseases, such as RSV and influenza.

CureVac’s mRNA technology uses optimized mRNA encoding F-protein to stimulate a protective and balanced immune response against RSV. For such optimized mRNA constructs, CureVac already holds a U.S. patent that supplements CureVac’s patent portfolio regarding RSV vaccination.

Vaccination of infants is especially difficult because they do not yet have fully established immune systems. Several efforts in the industry to develop and market a prophylactic RSV vaccine have failed to date. Therefore, vaccination of infants against RSV remains an unmet need and one of the major challenges for prophylactic vaccination.

This patent strengthens CureVac’s broad IP portfolio, among the most comprehensive in the industry, with more than 110 patent families, over 1,000 patent family members and more than 190 granted patents.

About RSV

RSV is a common respiratory virus and is the most common cause of bronchiolitis and pneumonia in children younger than one year of age in the U.S. An estimated 3.4 million children younger than five years of age are hospitalized each year with severe RSV lower respiratory tract infection, with the highest incidence in children younger than six months of age. RSV is second only to influenza as a cause of medically significant respiratory tract illnesses in adults and is estimated to cause 177,000 hospitalizations and 14,000 annual deaths in U.S. adults age 65 years and older. In the northern hemisphere and areas with similar climates, RSV infections occur primarily during fall, winter, and spring.1

About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.

To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s Dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.

For more information, please visit or follow us on Twitter at @CureVacAG.


Media Contact

Jenn Gordon, Media Relations Global Health PR, New York, United States T: +1 202-587-2580

Investor Contact

Matthew Beck, Vice President Investor Relations CureVac AG, Boston, MA, United States T: +1 917-415-1750

1 “Respiratory Syncytial Virus Infection” Centers for Disease Control and Prevention. June 2018. Last Accessed January 2019.

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for CureVac (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top